{{Use dmy dates|date=June 2013}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443383791
| IUPAC_name = 7-[(10,11-dihydro-5''H''-dibenzo[''a'',''d'']-cyclohepten-5-yl)amino]heptanoic acid
| image = Amineptine.svg
| width = 200px

<!--Clinical data-->
| tradename = Survector, others
| pregnancy_category = 
| legal_AU = Unscheduled
| legal_CA = Schedule III
| legal_DE = Anlage II
| legal_UK = Class C
| legal_UN = narcotic Schedule II
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = [[Hepatic]]
| elimination_half-life = Amineptine: 0.8–1.0 hours<ref name="pmid2714729" /><ref name="pmid7274306" /><br />Metabolite: 1.5–2.5 hours<ref name="pmid2714729" /><ref name="pmid7274306" />
| excretion = [[Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57574-09-1
| ATC_prefix = N06
| ATC_suffix = AA19
| PubChem = 34870
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04836
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 32091
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 27T1I13L6G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07335
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 32499
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 418995
| synonyms = S-1694

<!--Chemical data-->
| C=22 | H=28 | N=1 | O=2
| molecular_weight = 338.4653 g/mol
| SMILES = O=C(CCCCCCNC1C2=C(CCC3=C1C=CC=C3)C=CC=C2)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ONNOFKFOZAJDHT-UHFFFAOYSA-N
}}

'''Amineptine''', sold under the brand name '''Survector''' among others, is an [[atypical antidepressant]] of the [[tricyclic antidepressant]] (TCA) family.<ref name="pmid10371658">{{Cite journal|vauthors=Vaugeois JM, Corera AT, Deslandes A, Costentin J |title=Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor |journal=Pharmacology, Biochemistry, and Behavior |volume=63 |issue=2 |pages=285–90 |date=June 1999 |pmid=10371658 |doi=10.1016/S0091-3057(98)00242-1}}</ref><ref name="pmid17339521">{{cite journal |vauthors=Dunlop BW, Nemeroff CB |title=The role of dopamine in the pathophysiology of depression |journal=Arch. Gen. Psychiatry |volume=64 |issue=3 |pages=327–37 |year=2007 |pmid=17339521 |doi=10.1001/archpsyc.64.3.327 |url=}}</ref> It acts as a [[binding selectivity|selective]] and mixed [[dopamine reuptake inhibitor]] and [[dopamine releasing agent|releasing agent]], and to a lesser extent as a [[norepinephrine reuptake inhibitor]].<ref name="pmid10371658" /><ref name="pmid17339521" />

Amineptine was developed by the French Society of Medical research in the 1960s.<ref>DE Patent 2011806 - NEW TRICYCLIC DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE</ref> Introduced in France in 1978 by the [[pharmaceutical]] company [[Servier]],<ref name=amineptine_manufacture>{{Cite book | last = Sittig | first = Marshall | title = Pharmaceutical Manufacturing Encyclopedia | origyear = 1979 | url = http://www.amineptine.com/synthesis/manufacture.html | accessdate = 29 October 2005 | edition = 2nd | date = 1 April 1988 | publisher = William Andrew Publishing/Noyes Publications | location = Park Ridge, New Jersey, United States American | isbn = 0-8155-1144-2 | archiveurl= https://web.archive.org/web/20051023134339/http://www.amineptine.com/synthesis/manufacture.html| archivedate= 23 October 2005 <!--DASHBot-->| deadurl= no}}{{Page needed|date=September 2010}}</ref> amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, [[stimulant]] effect experienced by some patients. (This is to be distinguished from its antidepressant effect, which appears in approximately seven days after commencing treatment.)

After its release into the [[Europe]]an market, cases of [[hepatotoxicity]] emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.<ref>{{Cite web|title=Docket No. 02N-0101|publisher=U.S. Food and Drug Administration|date=2002-04-09|url=http://www.fda.gov/ohrms/dockets/98fr/040902a.htm |accessdate=2014-01-30}}</ref>

Amineptine was never approved by the U.S. [[Food and Drug Administration]] (FDA) for marketing in the United States, meaning that it is not legal to market or sell amineptine for any medical uses in the U.S.

{{TOC limit|3}}

==Medical uses==
Amineptine was approved in France for severe [[clinical depression]] of endogenous origin in 1978.<ref name=French_approval>{{cite web| author=Doctissimo | year=2005 |url=http://www.doctissimo.fr/medicament-SURVECTOR.htm | title=SURVECTOR - Amineptine| language = French | accessdate=27 October 2005 }}</ref>

==Contraindications==
* [[Chorea (disease)|Chorea]]
* [[Hypersensitivity]]: Known hypersensitivity to amineptine, in particular antecedents of hepatitis after dosage of the product.
* [[MAO inhibitor]]s

===Precautions for use===
Warnings and precautions before taking amineptine:<ref>[http://www.health-care-information.org/drugs/Amineptine.html Amineptine Medication - Uses, Side Effects and Precautions of Amineptine]. Health-care-information.org. Retrieved on September 28, 2013</ref>

* [[Breast feeding]]
* Children less than 15 year of age
* [[General anaesthesia]]: Discontinue the drug 24 to 48 hours before anaesthesia.{{Citation needed|date=September 2013}}
* Official sports/[[Olympic Games]]: Prohibited substance.
** 7 March Official Journal 2000.
* [[Pregnancy]] (first trimester){{Citation needed|date=September 2013}}

===Effects on the fetus===
* Lacking information in humans
* Non-[[teratogenic]] in rodents

==Side effects==

===Dermatological===
Severe [[Acne vulgaris|acne]] due to amineptine was first reported in 1988 by various authors&mdash;Grupper, Thioly-Bensoussan, Vexiau, Fiet, Puissant, Gourmel, Teillac, Levigne, to name a few&mdash;simultaneously<ref name=adv_acne_1988_1>{{Cite journal|author =Grupper C |title=[New iatrogenic acne: acne caused by amineptin (Survector)] |language=French |journal=Annales de dermatologie et de vénéréologie|volume=115 |issue=11 |pages=1174–6 |year=1988 |pmid=2977079}}</ref><ref name=adv_acne_1988_2>{{Cite journal|vauthors=Thioly-Bensoussan D, Charpentier A, Triller R |title=[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases] |language=French |journal=Annales de dermatologie et de vénéréologie |volume=115 |issue=11 |pages=1177–80 |year=1988 |pmid=2977080|display-authors=etal}}</ref><ref name=adv_acne_1988_3>{{Cite journal|vauthors=Vexiau P, Gourmel B, Husson C |title=[Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases] |language=French |journal=Annales de dermatologie et de vénéréologie |volume=115 |issue=11 |pages=1180–2 |year=1988 |pmid=2977081|display-authors=etal}}</ref><ref name=adv_acne_1988_4>{{Cite journal|vauthors=Teillac D, Weber MJ, Lowenstein W, de Prost Y |title=[Acne caused by Survector] |language=French |journal=Annales de dermatologie et de vénéréologie |volume=115 |issue=11 |pages=1183–4 |year=1988 |pmid=2977082}}</ref><ref name=adv_acne_1988_5>{{Cite journal|vauthors=Lévigne V, Faisant M, Mourier C |title=[Monstrous acne in the adult. Inducer role of Survector?] |language=French |journal=Annales de dermatologie et de vénéréologie |volume=115 |issue=11 |pages=1184–5 |year=1988 |pmid=2977083|display-authors=etal}}</ref> in the same issue of ''Annales de dermatologie et de vénéréologie'' and in the 12 March 1988 issue of ''The Lancet.''<ref name=Vexiau_et_al_1988_Lancet>{{Cite journal|vauthors=Vexiau P, Gourmel B, Julien R |title=Severe acne-like lesions caused by amineptine overdose |journal=Lancet |volume=1 |issue=8585 |page=585 |date=March 1988 |pmid=2894512 |doi=10.1016/S0140-6736(88)91373-6|display-authors=etal}}</ref> A year later, Dr Martin-Ortega and colleagues in Barcelona, Spain reported a case of "acneiform eruption" in a 54-year-old woman whose intake of amineptine was described as "excessive."<ref name=Martin-Ortega_et_al_1989>{{Cite journal|vauthors=Martín-Ortega E, Zamora E, Herrero C, Palou J |title=[Acneiform eruption induced by amineptin (Survector)] |language=Spanish |journal=Medicina Cutánea Ibero-latino-americana |volume=17 |issue=6 |pages=414–6 |year=1989 |pmid=2534534}}</ref> One year after that, Vexiau and colleagues reported six women, one of whom never admitted to using amineptine, getting severe acne concentrated in the face, back and [[thorax]], the severity of which varied with the dosage.<ref name=Vexiau_et_al_1990>{{Cite journal|vauthors=Vexiau P, Gourmel B, Castot A |title=Severe acne due to chronic amineptine overdose |journal=Archives of Dermatological Research |volume=282 |issue=2 |pages=103–7 |year=1990 |pmid=2141246 |doi=10.1007/BF00493467|display-authors=etal}}</ref> Most of them were treated unsuccessfully with [[isotretinoin]] (Accutane) for about 18 months; two of the three that discontinued amineptine experienced a reduction in cutaneous symptoms, with the least affected patient going into remission.<ref name=Vexiau_et_al_1990 />

===Psychiatric===
Psychomotor excitation can very rarely occur with this drug.

* [[Insomnia]]
* [[Irritability]]
* [[Anxiety|Nervousness]]
* [[Suicidal]] ideation. Seen early in the treatment, by lifting of psychomotor inhibition.

====Abuse and dependence====
The risk of [[Substance dependence|addiction]] is low, but exists nonetheless. Between 1978 and 1988, there were 186 cases of amineptine addiction reported to the French Regional Centres of Pharmacovigilance; an analysis of 155 of those cases found that they were predominantly female, and that two-thirds of cases had known risk factors for addiction.<ref name=Castot_et_al_1990>{{Cite journal|vauthors=Castot A, Benzaken C, Wagniart F, Efthymiou ML |title=[Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance] |language=French |journal=Thérapie |volume=45 |issue=5 |pages=399–405 |year=1990 |pmid=2260032}}</ref> However, a 1981 study of known [[opiate]] addicts and [[schizophrenia]] patients found no drug addiction in any of the subjects.<ref name=not_necessarily_addictive>{{Cite journal|vauthors=Deniker P, Lôo H, Zarifian E |title=[Amineptine and amotival syndrome (author's transl)] |language=French |journal=L'Encéphale |volume=7 |issue=1 |pages=59–64 |year=1981 |pmid=7227285|display-authors=etal}}</ref> In a 1990 study of eight amineptine dependence cases, the gradual withdrawal of amineptine could be achieved without problems in six people; in two others, [[anxiety]], psychomotor agitation, and/or [[bulimia]] appeared.<ref name=withdrawal_symptoms>{{Cite journal|vauthors=Bertschy G, Luxembourger I, Bizouard P, Vandel S, Allers G, Volmat R |title=[Amineptin dependence. Detection of patients at risk. Report of 8 cases] |language=French |journal=L'Encéphale |volume=16 |issue=5 |pages=405–9 |year=1990 |pmid=2265603}}</ref>

====Withdrawal====
Pharmacodependence is very common with amineptine compared to other antidepressants.<ref name="Blayac-">{{Cite journal  | last1 = Blayac | first1 = JP. | last2 = Hillaire-Buys | first2 = D. | last3 = Peyrière | first3 = H. | title = [Pharmacovigilance of new antidepressants: evaluation of neuro-psychobehavioral disorders] | journal = Therapie | volume = 52 | issue = 2 | pages = 117–22 | doi =  | pmid = 9231505 | year = 1997 }}</ref> A variety of psychological symptoms can occur during withdrawal from amineptine,<ref name="Castot-">{{Cite journal  | last1 = Castot | first1 = A. | last2 = Benzaken | first2 = C. | last3 = Wagniart | first3 = F. | last4 = Efthymiou | first4 = ML. | title = [Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance] | journal = Therapie | volume = 45 | issue = 5 | pages = 399–405 | doi =  | pmid = 2260032 | year = 1990 }}</ref> such as [[anxiety]] and agitation.<ref name="Bertschy-">{{Cite journal  | last1 = Bertschy | first1 = G. | last2 = Luxembourger | first2 = I. | last3 = Bizouard | first3 = P. | last4 = Vandel | first4 = S. | last5 = Allers | first5 = G. | last6 = Volmat | first6 = R. | title = [Amineptin dependence. Detection of patients at risk. Report of 8 cases] | journal = Encephale | volume = 16 | issue = 5 | pages = 405–9 | doi =  | pmid = 2265603 | year = 1990 }}</ref>

===Cardiovascular===
Very rarely:

* [[Arterial]] [[hypotension]]
* [[Palpitation]]s
* [[Vasomotor episode]]

===Hepatic===
Amineptine can rarely cause [[hepatitis]], of the [[cytolysis|cytolytic]], [[Hepatitis#Cholestatic|cholestatic]] varieties.<ref name=types_of_hepatitis>{{Cite journal|vauthors=Bories P, Pomier-Layrargues G, Chotard JP |title=[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)] |language=French |journal=La Nouvelle Presse Médicale |volume=9 |issue=48 |pages=3689–92 |date=December 1980 |pmid=7454584|display-authors=etal}}</ref> Amineptine-induced hepatitis, which is sometimes preceded by a rash, is believed to be due to an allergic reaction.<ref name=rash>{{Cite journal|vauthors=Pessayre D, Larrey D |title=Acute and chronic drug-induced hepatitis |journal=Baillière's Clinical Gastroenterology |volume=2 |issue=2 |pages=385–422 |date=April 1988 |pmid=3044468 |doi=10.1016/0950-3528(88)90009-7}}</ref> It resolves upon discontinuation of the offending drug.<ref name=types_of_hepatitis /> The risk of getting this may or may not be genetically determined.<ref name=genetic>{{Cite journal|vauthors=Larrey D, Pageaux GP |title=Genetic predisposition to drug-induced hepatotoxicity |journal=Journal of Hepatology |volume=26 |issue=Suppl 2 |pages=12–21 |year=1997 |pmid=9204405 |doi=10.1016/S0168-8278(97)80492-8}}</ref>

Additionally, amineptine is known to rarely elevate [[transaminase]]s, [[alkaline phosphatase]], and [[bilirubin]].<ref name=transaminase_etc>{{Cite journal|title=Questions au Professeur Daniel Dhumeaux |trans_title=Drug-induced liver disorders. Questions for Professor Daniel Dhumeaux |language=French |journal=Gastroentérologie Clinique et Biologique |volume=23 |issue=8–9 |pages=917–20 |year=1999 |pmid=10533145 |url=http://www.masson.fr/masson/MDOI-GCB-08-1999-23-8-9-0399-8320-101019-ART15}}</ref>

Mixed hepatitis, which is very rare, generally occurs between the 15th and 30th day of treatment. Often preceded by sometimes intense abdominal pains, nausea, vomiting or a rash, the jaundice is variable. Hepatitis is either of mixed type or with cholestatic prevalence. The evolution was, in all the cases, favorable to the discontinuation of the drug. The mechanism is discussed (immunoallergic and/or toxic).<ref>Concours Med 1982; 104:5733-5734{{Verify source|what's the rest of the bibliographic info?|date=December 2009}}</ref>

In circa 1994 Spain, there was a case associating acute pancreatitis and mixed hepatitis, after three weeks of treatment.<ref name=pancreatitis_and_hepatitis>{{Cite journal|vauthors=Sebastián Domingo JJ, Simón Marco MA, Uribarrena Echebarría R |title=Hepatic and pancreatic injury associated with amineptine therapy |journal=Journal of Clinical Gastroenterology |volume=18 |issue=2 |pages=168–9 |date=March 1994 |pmid=8189020 |doi=10.1097/00004836-199403000-00023}}</ref>

Lazaros and colleagues at the Western Attica General Hospital in [[Athens, Greece]] reported two cases of drug induced hepatitis 18 and 15 days of treatment.<ref name=Lazaros_et_al_1996>{{Cite journal|vauthors=Lazaros GA, Stavrinos C, Papatheodoridis GV, Delladetsima JK, Toliopoulos A, Tassopoulos NC |title=Amineptine induced liver injury. Report of two cases and brief review of the literature |journal=Hepato-gastroenterology |volume=43 |issue=10 |pages=1015–9 |year=1996 |pmid=8884331}}</ref>

One case of cytolytic hepatitis occurred after ingestion of only one tablet.<ref name=Jonville_Dutertre_Autret_1992>{{Cite journal|vauthors=Jonville AP, Dutertre JP, Autret E |title=[Immediate acute hepatic cytolysis after the administration of a single amineptin tablet] |language=French |journal=Gastroentérologie Clinique et Biologique |volume=16 |issue=4 |page=368 |year=1992 |pmid=1397859}}</ref>

===Gastrointestinal===
* Acute pancreatitis (very rare) A case associating acute [[pancreatitis]] and mixed hepatitis after three weeks of treatment.<ref name=pancreatitis_and_hepatitis />

===Immunological===
In 1989, Sgro and colleagues at the [[Pharmacovigilance|Centre de Pharmacovigilance]]<ref>[http://www.centres-pharmacovigilance.net centres-pharmacovigilance.net]  {{webarchive|url=https://web.archive.org/web/20120208155510/http://www.centres-pharmacovigilance.net/ |date=8 February 2012 }}</ref> in [[Dijon]] reported a case of [[anaphylactic shock]] in a woman who had been taking amineptine.<ref name=anaphylaxis>{{Cite journal|vauthors =Sgro C, Lacroix S, Waldner A, Lacroix M, Ferrut O, Bureau A |title=[Anaphylactic shock caused by amineptine. Report of a case] |language=French |journal=[[La Revue de Médecine Interne]] |volume=10 |issue=5 |pages=461–2 |year=1989 |pmid=2488491 |doi=10.1016/s0248-8663(89)80054-2}}</ref>

==Pharmacology==

===Pharmacodynamics===
{| class="wikitable floatright" style="font-size:small;"
|+ Amineptine<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | format = HTML | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=amineptine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| {{abbrlink|SERT|Serotonin transporter}} || >100,000 ([[IC50|IC<sub>50</sub>]]) || Rat || <ref name="pmid2698268" />
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''10,000 (IC<sub>50</sub>)<br />3,560''' || '''Rat<br />Canine''' || <ref name="pmid2698268">{{cite journal |vauthors=Garattini S, Mennini T |title=Pharmacology of amineptine: synthesis and updating |journal=Clin Neuropharmacol |volume=12 Suppl 2 |issue= |pages=S13–8 |year=1989 |pmid=2698268 |doi= |url=}}</ref><ref name="pmid3708219" /><br /><ref name="pmid11382857">{{cite journal |vauthors=Nishino S, Mao J, Sampathkumaran R, Shelton J |title=Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants |journal=Sleep Res Online |volume=1 |issue=1 |pages=49–61 |year=1998 |pmid=11382857 |doi= |url=}}</ref>
|-
| '''{{abbrlink|DAT|Dopamine transporter}}''' || '''1,000–1,400 (IC<sub>50</sub>)<br />3,330''' || '''Rat<br />Canine''' || <ref name="pmid2698268" /><ref name="pmid8676127">{{cite journal |vauthors=Protais P, Arbaoui J, Bakkali EH, Bermejo A, Cortes D |title=Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes |journal=J. Nat. Prod. |volume=58 |issue=10 |pages=1475–84 |year=1995 |pmid=8676127 |doi= |url=}}</ref><ref name="pmid3708219">{{cite journal |vauthors=Ceci A, Garattini S, Gobbi M, Mennini T |title=Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain |journal=Br. J. Pharmacol. |volume=88 |issue=1 |pages=269–75 |year=1986 |pmid=3708219 |pmc=1917102 |doi= |url=}}</ref><br /><ref name="pmid11382857" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || >100,000 || Rat || <ref name="pmid6464782">{{cite journal |vauthors=Hall H, Sällemark M, Wedel I |title=Acute effects of atypical antidepressants on various receptors in the rat brain |journal=Acta Pharmacol Toxicol (Copenh) |volume=54 |issue=5 |pages=379–84 |year=1984 |pmid=6464782 |doi= |url=}}</ref>
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 74,000 || Rat || <ref name="pmid6464782" />
|-
| [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] || >100,000 || Rat || <ref name="pmid6464782" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || >100,000 || Rat || <ref name="pmid6464782" />
|-
| [[Beta-adrenergic receptor|β]] || >100,000 || Rat || <ref name="pmid6464782" />
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || >100,000 || Canine || <ref name="pmid2698268" />
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || >100,000 || Rat/canine || <ref name="pmid2698268" /><ref name="pmid6464782" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || >100,000<br />'''13,000''' || Rat<br />'''Guinea pig''' || <ref name="pmid6464782" /><br /><ref name="pmid6141518">{{cite journal |vauthors=Hall H, Ogren SO |title=Effects of antidepressant drugs on histamine-H1 receptors in the brain |journal=Life Sci. |volume=34 |issue=6 |pages=597–605 |year=1984 |pmid=6141518 |doi= |url=}}</ref>
|-
| {{abbrlink|mACh|Muscarinic acetylcholine receptor}} || >100,000 || Rat || <ref name="pmid6464782" />
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.
|}

Amineptine [[reuptake inhibitor|inhibit]]s the [[reuptake]] of [[dopamine]] and, to a much lesser extent, of [[norepinephrine]].<ref name="pmid3708219" /><ref name="pmid2698268" /><ref name="pmid9347388">{{cite journal |vauthors=Garattini S |title=Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review |journal=Int Clin Psychopharmacol |volume=12 Suppl 3 |issue= |pages=S15–9 |year=1997 |pmid=9347388 |doi= |url=}}</ref> In addition, it has been found to [[releasing agent|induce the release]] of dopamine.<ref name="pmid3708219" /><ref name="pmid2698268" /><ref name="pmid9347388" /> However, amineptine is much less efficacious as a [[dopamine releasing agent]] relative to [[dextroamphetamine|<small>D</small>-amphetamine]], and the drug appears to act predominantly as a [[dopamine reuptake inhibitor]].<ref name="pmid3708219" /><ref name="pmid2698268" /><ref name="pmid9347388" /> In contrast to the case for dopamine, amineptine does not induce the release of norepinephrine, and hence acts purely as a [[norepinephrine reuptake inhibitor]].<ref name="pmid3708219" /><ref name="pmid2698268" /><ref name="pmid9347388" /> Unlike other TCAs, amineptine interacts very weakly or not at all with the [[serotonin receptor|serotonin]], [[adrenergic receptor|adrenergic]], [[dopamine receptor|dopamine]], [[histamine receptor|histamine]], and [[muscarinic acetylcholine receptor]]s.<ref name="pmid6464782" /><ref name="pmid6141518" /><ref name="pmid9347388" /> The major [[metabolite]]s of amineptine have similar activity to that of the parent compound, albeit with lower [[potency (pharmacology)|potency]].<ref name="pmid9347388" />

No human data appear to be available for binding or inhibition of the [[monoamine transporter]]s by amineptine.<ref name="pmid19557250">{{cite journal |vauthors=Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K |title=Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters |journal=Chem. Commun. (Camb.) |volume= |issue=25 |pages=3677–92 |year=2009 |pmid=19557250 |doi=10.1039/b903035m |url=}}</ref>

===Pharmacokinetics===
[[Cmax (pharmacology)|Peak plasma levels]] of amineptine following a single 100&nbsp;mg oral dose have been found to range between 277 and 2,215&nbsp;ng/mL (818–6,544&nbsp;nM), with a mean of 772&nbsp;ng/mL (2,281&nbsp;nM), whereas maximal plasma concentrations of its major [[metabolite]]<!--309.409 g/mol--> ranged between 144 and 1,068&nbsp;ng/mL (465–3,452&nbsp;nM), with a mean of 471&nbsp;ng/mL (1,522&nbsp;nM).<ref name="pmid2714729">{{cite journal |vauthors=Lachatre G, Piva C, Riche C, et al. |title=Single-dose pharmacokinetics of amineptine and of its main metabolite in healthy young adults |journal=Fundam Clin Pharmacol |volume=3 |issue=1 |pages=19–26 |year=1989 |pmid=2714729 |doi= |url=}}</ref> After a single 200&nbsp;mg oral dose of amineptine, mean peak plasma levels of amineptine were around 750 to 940&nbsp;ng/mL (2,216–2,777&nbsp;nM), while those of its major metabolite were about 750 to 970&nbsp;ng/mL (2,216–3,135&nbsp;nM).<ref name="pmid7274306">{{cite journal |vauthors=Sbarra C, Castelli MG, Noseda A, Fanelli R |title=Pharmacokinetics of amineptine in man |journal=Eur J Drug Metab Pharmacokinet |volume=6 |issue=2 |pages=123–6 |year=1981 |pmid=7274306 |doi= |url=}}</ref> The [[Tmax (pharmacology)|time to peak concentrations]] is about 1&nbsp;hour for amineptine and 1.5&nbsp;hours for its major metabolite.<ref name="pmid2714729" /><ref name="pmid7274306" /> The [[elimination half-life]] of amineptine is about 0.80 to 1.0&nbsp;hours and that of its major metabolite is about 1.5 to 2.5&nbsp;hours.<ref name="pmid2714729" /><ref name="pmid7274306" /> Due to their very short elimination half-lives, amineptine and its major metabolite do not accumulate significantly with repeated administration.<ref name="pmid2714729" />

==Society and culture==

===Brand names===
Amineptine has been sold under a variety of brand names including '''Survector''', '''Maneon''', '''Directim''', '''Neolior''', '''Provector''', and '''Viaspera'''.

==See also==
* [[Medifoxamine]]
* [[Nomifensine]]
* [[Tianeptine]]

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Stimulants}}
{{Monoamine reuptake inhibitors}}
{{Monoamine releasing agents}}
{{Tricyclics}}

[[Category:Amines]]
[[Category:Carboxylic acids]]
[[Category:Dibenzocycloheptenes]]
[[Category:Dopamine releasing agents]]
[[Category:Hepatotoxins]]
[[Category:Laboratoires Servier]]
[[Category:Norepinephrine-dopamine reuptake inhibitors]]
[[Category:Tricyclic antidepressants]]
[[Category:Withdrawn drugs]]